NEWS SEARCH ANALYSIS INSIGHT

360° SearchNetwork Hot Spots Trends

Advanced Search Options >>

Friday, March 19, 2010 5:51 PM

Acute Coronary Syndrome

Type: Keyphrase

Name: Acute Coronary Syndrome

First Reported 4 hours ago - Updated 4 hours ago - 1 Documents

Ticagrelor Shows Lower Mortality Than Clopidogrel After CABG

– New Results from PLATO trial suggest ticagrelor (Brilinta) leads to lower mortality and no increased risk of bleeding when compared to clopidogrel (Plavix) in patients with acute coronary syndrome who undergo coronary artery bypass graft (CABG) sur ... [Published 4 hours ago by Diagnostic & Invasive Cardiology]

Entities: Clopidogrel, thrombocyte, Acute Coronary Syndrome, Mortality

First Reported Mar 17 2010 - Updated Mar 17 2010 - 1 Documents

ACC: Ticagrelor Is Promising Alternative to Clopidogrel

TUESDAY, March 16 (HealthDay News) -- The use of ticagrelor instead of clopidogrel in patients with acute coronary syndrome who undergo coronary artery bypass graft (CABG) surgery is associated with a lower likelihood of fatal outcomes, according to research ... [Published Mar 17 2010 by Modern Medicine]

Entities: Clopidogrel, Acute Coronary Syndrome, Heart Attack, thrombocyte

First Reported Mar 16 2010 - Updated Mar 16 2010 - 1 Documents

B-Type Natriuretic Peptide and the Effect of Ranolazine in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes

Morrow DA et al. The findings indicate that ranolazine may have enhanced efficacy in highrisk patients with ACS identified by increased BNP. The interaction of biomarkers of hemodynamic stress and the effects of ranolazine warrants additional investi ... [Published Mar 16 2010 by MDLinx]

Entities: Acute Coronary Syndrome, Peptide, Ranolazine

First Reported Mar 14 2010 - Updated Mar 14 2010 - 1 Documents

New meta-analysis: Routine invasive strategy betters selective care for non-ST-elevation ACS

A more aggressive routine invasive strategy is clearly better than a conservative selective invasive strategy for all patients with non-ST-elevation acute coronary syndromes, a new meta-analysis shows. And the highest-risk patients had the most to gain, ... [Published Mar 14 2010 by Theheart.org]

Entities: Acute Coronary Syndrome, Stratification

First Reported Mar 09 2010 - Updated Mar 10 2010 - 2 Documents

Stentys self-expanding stent secures approval in Europe

Stentys has received CE Mark approval for its self-expanding stent, which is aimed at treating acute coronary syndrome. - More -Free Webinar: Clinical Evaluation 101 for Medical Devices: A Key Requirement to Gaining Access to the European Market. Are ... [Published Mar 10 2010 by SmartBrief]

Entities: Stent, Acute Coronary Syndrome, CE Mark

First Reported Mar 07 2010 - Updated Mar 07 2010 - 2 Documents

Shionogi

Anthera Off to a Humble Start

The Burrill Report submits: Freshly minted shares of Anthera Pharmaceuticals (ANTH) sold for just half their original target price during the company's March 1 IPO, raising merely $42 million instead of the anticipated $70 million. Concurrently, ... [Published Mar 07 2010 by IPO Analysis from Seeking Alpha]

Entities: IPO, Shionogi, Anthera Pharmaceuticals Inc, Acute Coronary Syndrome

First Reported Mar 05 2010 - Updated Mar 06 2010 - 3 Documents

Stentys Self-Expanding Stent Receives CE Mark for Acute Coronary Syndrome

Medical device pioneer Stentys announced that it has receivedCE Marking for its self-expanding and disconnectable stent to treat acute coronary syndrome. ... [Published Mar 05 2010 by FDA News]

Entities: Acute Coronary Syndrome, Stent, CE Mark

First Reported Feb 25 2010 - Updated Feb 25 2010 - 2 Documents

In the Acute Coronary Syndrome Drug Market, the Uptake of Eli Lil...

In the Acute Coronary Syndrome Drug Market, the Uptake of Eli Lilly/Daiichi Sankyo's Effient Will Be Constrained by the Widespread Use of Astrazeneca's BrilintaWALTHAM, Mass., Feb 25, 2010 /PRNewswire via COMTEX/ --Companies: ADP (AEOPF), Bristol-Myers ... [Published Feb 25 2010 by Zibb]

Entities: Acute Coronary Syndrome, Brilinta, Plavix, Eli Lilly & Company

First Reported Feb 23 2010 - Updated Feb 23 2010 - 1 Documents

A tale of two patients

It was the best of shifts, it was the worst of shifts.....it was also a typical busy day in the life of any medical SHO across the NHS. It has been an odd experience for me coming back to work in a large, city teaching hospital after the last 6 months ... [Published Feb 23 2010 by OnMedicanet]

Entities: Bolivia, NHS, Coronary Care Unit., Occupational Therapist, Acute Coronary Syndrome

First Reported Feb 19 2010 - Updated Feb 19 2010 - 1 Documents

Correlation of Inhibition of Platelet Aggregation With Cardiovascular and Bleeding Outcomes in Acute Coronary Syndromes

Wada R et al. Target IPA increases in ACS are an absolute increase of 80% for IV GP2b/3a antagonists and 30% for thienopyridines. Quantitative models using literature data on IPA and CV events can be used to select dose regimens in early stages of drug ... [Published Feb 19 2010 by MDLinx]

Entities: Acute Coronary Syndrome, World Anti-Doping Agency

First Reported Feb 18 2010 - Updated Feb 18 2010 - 1 Documents

Initial Clopidogrel Response May Predict Final Response

In patients with acute coronary syndrome, a slow clopidogrel response within the first hour afterloading may identify those with a low response after 24 hours and high post-treatment platelet reactivity,according to a study in the Feb. 23 issue of the ... [Published Feb 18 2010 by Modern Medicine]

Entities: Clopidogrel, Acute Coronary Syndrome, American College of Cardiology

First Reported Feb 17 2010 - Updated Feb 17 2010 - 2 Documents

SPA for Antheras Varespladib Confirmed by FDA

Anthera Pharmaceuticals and the FDA have agreed on a special protocol assessment (SPA) for a Phase III trial of the companys acute coronary syndrome candidate varespladib. The company expects to begin the Phase III trial in the first half of this year ... [Published Feb 17 2010 by FDA News]

Entities: Food and Drug Administration, Phase III Trial, Anthera Pharmaceuticals Inc

Quotes

...to medication," said Jessica Mega, M D , M P H , associate physician at Brigham and Women s Hospital and investigator at the TIMI Study Group. "Understanding the full scope of these genetic variations may help determine which drug to prescribe as part of the dual antiplatelet therapy a patient receives after an angioplasty with a stent."

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene [News-Medical.Net - Mar 17 2010]

"These treatment comparisons were consistent with the effects seen in the overall PLATO trial" said Dr. Claes Held

Primary results of CABG sub-analysis presented at ACC meeting [News-Medical.Net - Mar 17 2010]

"Ticagrelor seems to be a very promising alternative to clopidogrel for patients with acute coronary syndrome who might be candidates for CABG surgery, because of the significant reduction in mortality and the similar bleeding rate" Held said in a statement

ACC: Ticagrelor Is Promising Alternative to Clopidogrel [Modern Medicine - Mar 17 2010]

More Content

sort by: Date \| Relevance
Ticagrelor Shows Lower Mortality Than Clopidogr... [Diagnostic & Invasive Cardiology - 4 hours ago]
TopAbstracts in Congestive Heart Failure 03/18/... [Doctors Guide - 12 hours ago]
PLATO: Ticagrelor lowers total and CV mortality... [MedWire News - 15 hours ago]
AstraZeneca says PLATO study shows fewer deaths... [PharmaBiz - Mar 18 2010]
TRITON-TIMI 38 study evaluates response rates i... [News-Medical.Net - Mar 17 2010]
Primary results of CABG sub-analysis presented ... [News-Medical.Net - Mar 17 2010]
ACC: Ticagrelor Is Promising Alternative to Clo... [Modern Medicine - Mar 17 2010]
Newer Blood Thinner Beats Plavix for Bypass Pat... [MSN - Mar 16 2010]
ACC: CABG Data Suggest Ticagrelor Benefit [MedPage Today - Mar 16 2010]
Study Points to Role of ABCB1 Gene Alterations ... [GenomeWeb - Mar 16 2010]
Meta-analysis: Routine Invasive Strategy Holds ... [TCTMD.com - Mar 16 2010]
New tool to predict early death or hospital rea... [Science Centric - Mar 16 2010]
B-Type Natriuretic Peptide and the Effect of Ra... [MDLinx - Mar 16 2010]
Plavix Response Reduced for Patients With CYP2C... [National AIDS Treatment Advocacy Project - Mar 15 2010]
Ticagrelor effective in nonresponders to clopid... [MedWire News - Mar 15 2010]
Centennial Medical Center Receives Chest Pain C... [dBusinessNews.com - Mar 15 2010]
Siemens' Commitment to Excellence in Cardiology... [Medicexchange.com - Mar 15 2010]
New meta-analysis: Routine invasive strategy be... [Theheart.org - Mar 14 2010]
Siemens Highlights Its Commitment to Excellence... [Earthtimes.org - Mar 14 2010]
AVEO Squeezes $81M Out of IPO Window; No Fools ... [BioWorld - Mar 14 2010]
FDA Issues Boxed Warning for CYP2C19-Linked Poo... [GenomeWeb - Mar 13 2010]
Sanofi-aventis and Bristol-Myers Squibb Announc... [Zibb - Mar 12 2010]
Sanofi-aventis and Bristol-Myers Squibb Announc... [Business Wire via MSN Money - Mar 12 2010]
Sanofi-aventis and Bristol-Myers Squibb Announc... [Forbes.com - Mar 12 2010]
Sanofi-aventis and Bristol-Myers Squibb Announc... [FinanzNachrichten.de - Mar 12 2010]
XOMA Ltd. Q4 2009 Earnings Call Transcript [Seeking Alpha - Mar 12 2010]
New oral anticoagulants may replace warfarin [Hemonctoday - Mar 11 2010]
Women with acute coronary syndrome are less inv... [MDLinx - Mar 11 2010]
Stentys self-expanding stent secures approval i... [SmartBrief - Mar 10 2010]
High-sensitivity troponin T test improves sensi... [MedWire News - Mar 10 2010]

Blogs

sort by: Date \| Relevance
Anthera Off to a Humble Start [IPO Analysis from Seeking Alpha - Mar 07 2010] The Burrill Report submits: Freshly minted shares of Anthera Pharmaceuticals (ANTH) sold for just half their original target price during the company's March 1 IPO, ...
Anthera Off to a Humble Start [Biotech Sector and Stocks Analysis from Seeking ... - Mar 07 2010] The Burrill Report submits: Freshly minted shares of Anthera Pharmaceuticals (ANTH) sold for just half their original target price during the company's March 1 IPO, ...
Cytomegalovirus and Heart Disease [Aetiology] [ScienceBlogs : Combined Feed - Feb 23 2010] Student guest post by Dayna Groskreutz Heart disease is the leading cause of death in adults in the United States. Acute coronary syndrome (ACS) is a term which ...
BioMed News Bytes: AstraZeneca, Delcath, Unilife [Healthcare Sector and Stocks Analysis from Seek ... - Nov 20 2009] Mike Havrilla submits:On 11/19/09, AstraZeneca (NYSE: AZN) announced the submission of a New Drug Application (NDA) to the FDA for ticagrelor, an investigational ...
BioMed News Bytes: AstraZeneca, Delcath, Unilife [Biotech Sector and Stocks Analysis from Seeking ... - Nov 20 2009] Mike Havrilla submits:On 11/19/09, AstraZeneca (NYSE: AZN) announced the submission of a New Drug Application (NDA) to the FDA for ticagrelor, an investigational ...